Search

Your search keyword '"Blanchet, Benoît"' showing total 25 results
Start Over Author "Blanchet, Benoît" Search Limiters Peer Reviewed Publication Year Range Last 10 years
25 results on '"Blanchet, Benoît"'

1. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort.

Author

Nguyen, Yann, Blanchet, Benoît, Urowitz, Murray, Hanly, John, Gordon, Caroline, Bae, Sang-Cheol, Romero-Diaz, Juanita, Sanchez-Guerrero, Jorge, Clarke, Ann, Bernatsky, Sasha, Wallace, Daniel, Isenberg, David, Rahman, Anisur, Merrill, Joan, Fortin, Paul, Gladman, Dafna, Bruce, Ian, Petri, Michelle, Ginzler, Ellen, Dooley, Mary, Ramsey-Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela, Van Vollenhoven, Ronald, Aranow, Cynthia, Le Guern, Véronique, Mackay, Meggan, Ruiz-Irastorza, Guillermo, Lim, S, Inanc, Murat, Jacobsen, Søren, Peschken, Christine, Kamen, Diane, Askanase, Anca, Buyon, Jill, Costedoat-Chalumeau, Nathalie, and Kalunian, Kenneth

Subjects
Humans, Female, Male, Hydroxychloroquine, Lupus Erythematosus, Systemic, Prednisone, Immunosuppressive Agents, Proportional Hazards Models
Abstract

OBJECTIVE: The goals of this study were to assess the associations of severe nonadherence to hydroxychloroquine (HCQ), objectively assessed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates over five years of follow-up. METHODS: The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort is an international multicenter initiative (33 centers throughout 11 countries). The serum of patients prescribed HCQ for at least three months at enrollment were analyzed. Severe nonadherence was defined by a serum HCQ level

Published
2023

2. Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?

Author

Renard, Perrine, Caccavelli, Laure, Legendre, Antoine, Tuchmann-Durand, Caroline, Balakirouchenane, David, Blanchet, Benoit, Narjoz, Céline, Straube, Marjolène, Hubas, Arnaud, Garros, Alexa, Mention, Karine, Bednarek, Nathalie, Goudin, Nicolas, Broissand, Christine, Schlatter, Joel, Cisternino, Salvatore, Cagnard, Nicolas, van Endert, Peter, Diana, Julien, de Calbiac, Hortense, and de Lonlay, Pascale

Published
2023
Full Text
View/download PDF

7. LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort

Author

Nguyen, Yann, primary, Blanchet, Benoît, additional, Urowitz, Murray B, additional, Hanly, John G, additional, Gordon, Caroline, additional, Bae, Sang-Cheol, additional, Romero-Diaz, Juanita, additional, Sanchez-Guerrero, Jorge, additional, Clarke, Ann E, additional, Bernatsky, Sasha, additional, Wallace, Daniel J, additional, Isenberg, David A, additional, Rahman, Anisur, additional, Merrill, Joan T, additional, Fortin, Paul R, additional, Gladman, Dafna D, additional, Bruce, Ian N, additional, Petri, Michelle, additional, Ginzler, Ellen M, additional, Dooley, Mary Anne, additional, Ramsey-Goldman, Rosalind, additional, Manzi, Susan, additional, Jönsen, Andreas, additional, Alarcón, Graciela S, additional, Vollenhoven, Ronald FVan, additional, Aranow, Cynthia, additional, Guern, Véronique Le, additional, Mackay, Meggan, additional, Ruiz-Irastorza, Guillermo, additional, Lin, Sam, additional, Inanc, Murat, additional, Kalunian, Kenneth C, additional, Jacobsen, Søren, additional, Peschken, Christine A, additional, Kamen, Diane L, additional, Askanase, Anca, additional, Buyon, Jill, additional, and Costedoat-Chalumeau, Nathalie, additional

Published
2023
Full Text
View/download PDF

9. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.

Author

Balakirouchenane, David, Seban, Romain, Groussin, Lionel, Puszkiel, Alicja, Cottereau, Anne Ségolène, Clerc, Jerome, Vidal, Michel, Goldwasser, Francois, Arrondeau, Jennifer, Blanchet, Benoît, and Huillard, Olivier

Subjects
IODINE isotopes, THYROID cancer, DRUG utilization, ELECTRONIC health records, PHARMACOKINETICS, PHARMACODYNAMICS
Abstract

Background: BRAF and MEK inhibitors are cornerstones of the redifferentiation strategy in metastatic radioactive iodine (RAI)-resistant mutant thyroid cancers. We explored the exposure–toxicity relationship for dose-limiting toxicity (DLT) onset in patients treated with dabrafenib and/or trametinib and investigated whether plasma exposure was associated with RAI reuptake. Methods: We conducted a retrospective monocentric study in which we reviewed the electronic medical records of patients treated in our institution with a tumor redifferentiation strategy, for whom plasma concentration of dabrafenib, its active metabolite hydroxy-dabrafenib, and trametinib was measured. Trough concentrations (Cminpred) and total plasma drug exposure (area under the curve, AUC) of dabrafenib (AUCDAB), hydroxy-dabrafenib (AUCOHD), and trametinib (AUCTRA) were estimated. Results: Of the 22 patients treated in a redifferentiation strategy between March 2014 and December 2021, 15 were included in this study. A dabrafenib- or trametinib-related DLT was experienced by 8 (62%) and 9 (64%) patients, respectively. Patients who experienced a trametinib-related DLT exhibited a significantly higher last AUCTRA than the average AUCTRA of patients who had no DLT (390, IQR: 67 vs. 215, IQR: 91 ng/mL·h−1, respectively; p = 0.008). Patients who experienced a dabrafenib-related DLT had a higher AUCDAB than observed in other patients (9265 ng/mL·h−1 vs. 6953 ng/mL·h−1, respectively; p = 0.09). No clinical and demographical characteristic was associated with the DLT onset. Overall, 9 of 15 (60%) patients demonstrated tumor redifferentiation. Patients in whom RAI reuptake was achieved had significant lower AUCDAB (6990 ng/mL·h−1 vs. 9764 ng/mL·h−1, p = 0.014; respectively) compared with patients who did not. Moreover, the relative exposure ratio of AUCOHD/DAB was significantly higher in patients who achieved RAI reuptake (1.11 vs. 0.71, respectively; p = 0.0047). Conclusions: Our data suggest a relationship between DLT onset and trametinib plasma exposure, as well as an association between achievement of RAI reuptake and dabrafenib plasma exposure (AUC and ratio of AUCOHD/DAB). These data imply that the use of plasma drug monitoring could be helpful in guiding clinical practice in redifferentiation treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients

Author

Bonnet-Serrano, Fidéline, primary, Poirier, Jonathan, additional, Vaczlavik, Anna, additional, Laguillier-Morizot, Christelle, additional, Blanchet, Benoît, additional, Baron, Stéphanie, additional, Guignat, Laurence, additional, Bessiene, Laura, additional, Bricaire, Léopoldine, additional, Groussin, Lionel, additional, Assié, Guillaume, additional, Guibourdenche, Jean, additional, and Bertherat, Jérôme, additional

Published
2022
Full Text
View/download PDF

19. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

Author

Reis, Rafael, Labat, Laurence, Allard, Marie, Boudou-Rouquette, Pascaline, Chapron, Jeanne, Bellesoeur, Audrey, Thomas-Schoemann, Audrey, Arrondeau, Jennifer, Giraud, Frédérique, Alexandre, Jérôme, Vidal, Michel, Goldwasser, François, and Blanchet, Benoît

Published
2018
Full Text
View/download PDF

20. Genetics of digestive efficiency in growing pigs fed a conventional or a high‐fibre diet.

Author

Déru, Vanille, Bouquet, Alban, Labussière, Etienne, Ganier, Philippe, Blanchet, Benoît, Carillier‐Jacquin, Céline, and Gilbert, Hélène

Subjects
NEAR infrared spectroscopy, ANIMAL carcasses, SWINE breeding, ANIMAL nutrition, SWINE, GENETIC correlations, MEAT quality
Abstract

The use of diets with increased dietary fibre content (HF) from alternative feedstuffs is a solution to limit the impact of increased feed costs on pig production. This study aimed at determining the impact of an alternative HF diet on pig digestibility and at estimating genetic parameters of this trait. Digestibility coefficients (DC) of energy, organic matter and nitrogen were predicted from faecal samples analysed with near infrared spectrometry for 1,242 samples, and it represented 654 Large White pigs fed a conventional (CO) diet and 588 fed a HF diet. Growth and feed efficiency traits, carcass composition and meat quality traits were recorded. Pigs fed the HF diet had significantly lower DC than pigs fed the CO diet (−4.5 to 6.0 points). The DC were moderately to highly heritable (about 0.26 ± 0.12 and 0.54 ± 0.15 in the CO and the HF diet, respectively). Genetic correlations were favourable with feed conversion ratio, daily feed intake and residual feed intake, but unfavourable with average daily gain (ADG) and carcass yield (CY). To conclude, DC could be an interesting trait to include in future breeding objectives if pigs were fed diet with HF diets, but adverse genetic trends with ADG and CY would have to be taken into account. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results